oxymorphone trials begin, page-13

Well, that is a very complkex announcement..lots of insights for us to take into account...

Firstly we will know how the performance of the new Labtech Patch works in humans withinn a the next 2 months.

If, and we expect it to be, it is successful, that will give us a very strong confidence boost for OXYCODONE trials.

The wording of the announcement indicayes this new product just might have the potential to outsell the OXYCODONE...That sales growth for OXYMORPHONE could just explode with a thumb size patch as JM mentioned.

Big Pharma would be on the phone to Harry right now. NEURA probably well engaged in discussions withem all anyway.

So how valuable will POH be after OPH1 trials show Labtech Patch works, and just a few short months from taking both Patches into Phase2/3 trials simultaneously.

Should in reality be worth far more than QRX or ACR were at similar points.

Especially with more OPIODPATCHES under review.

This was a very serious value creating announcement. I don't expect these idots who run Ausdtralian Investment Funds to understand it. But US big Pharma will.